Who Makes Zepbound? The Manufacturer, FDA Approval, and Supply Chain Behind the Drug

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 9 sources cited

Key Takeaways

• Zepbound is made by Eli Lilly and Company, an Indianapolis-based pharmaceutical manufacturer founded in 1876.
• The active ingredient is tirzepatide, a dual GIP and GLP-1 receptor agonist that Lilly developed and patented.
• The FDA approved Zepbound for chronic weight management on November 8, 2023.
• Zepbound is manufactured at Lilly facilities in Indianapolis, Indiana and Concord, North Carolina, with new manufacturing capacity added at Pleasant Prairie, Wisconsin and Lebanon, Indiana.
• Tirzepatide is also sold by Lilly under the brand name Mounjaro for type 2 diabetes. Both products contain the same active ingredient at the same doses.

Direct answer (40-60 words)

Zepbound is manufactured by Eli Lilly and Company, an American pharmaceutical company headquartered in Indianapolis, Indiana. Lilly developed and patented the active ingredient, tirzepatide, and won FDA approval for Zepbound on November 8, 2023, as a treatment for chronic weight management in adults with obesity or overweight with weight-related conditions.

Table of contents

1. The 30-second answer
2. Eli Lilly: who they are and their GLP-1 history
3. How Zepbound got from lab to market
4. FDA approval details
5. Where Zepbound is manufactured
6. Zepbound vs Mounjaro: same drug, different brand
7. The active ingredient: tirzepatide
8. Supply chain and shortage history
9. The compounding question
10. FAQ
11. Sources

Eli Lilly: who they are and their GLP-1 history

Eli Lilly and Company is one of the largest pharmaceutical manufacturers in the world. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company has been continuously based there for nearly 150 years. Lilly is publicly traded on the New York Stock Exchange under the ticker LLY.

Lilly's GLP-1 history is older than most patients realize. The company launched exenatide (Byetta) in 2005 in partnership with Amylin Pharmaceuticals; this was one of the first GLP-1 receptor agonists approved in the United States. Lilly later developed dulaglutide (Trulicity), approved by the FDA in 2014, which became one of the most-prescribed GLP-1 medications globally for type 2 diabetes.

Tirzepatide was Lilly's next-generation GLP-1 program. Unlike single-receptor GLP-1 agonists, tirzepatide acts on both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. The dual-receptor mechanism produced larger weight loss in clinical trials than single-receptor GLP-1 drugs.

Lilly markets tirzepatide under two brand names:

• Mounjaro for adults with type 2 diabetes (FDA-approved May 2022)
• Zepbound for chronic weight management (FDA-approved November 2023)

How Zepbound got from lab to market

The development timeline:

The total development time, from early-stage research to FDA approval, was approximately 15 years. Phase 3 clinical trials alone enrolled more than 12,000 patients across the SURPASS and SURMOUNT programs.

FDA approval details

The FDA approved Zepbound on November 8, 2023, for chronic weight management in adults who meet either of these criteria:

• BMI of 30 kg/m² or greater (obesity), or
• BMI of 27 kg/m² or greater (overweight) with at least one weight-related condition such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease

The approval was based on the SURMOUNT-1 and SURMOUNT-2 trials. SURMOUNT-1 enrolled adults with obesity but without type 2 diabetes; SURMOUNT-2 enrolled adults with obesity and type 2 diabetes. Both showed substantial weight loss versus placebo.

In December 2024, the FDA expanded Zepbound's indication to include treatment of moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trial.

The Zepbound label was updated in 2025 to reflect newer cardiovascular and renal data from the SURMOUNT-MMO trial.

Where Zepbound is manufactured

Zepbound is manufactured at Lilly facilities in the United States. The primary manufacturing sites are:

Lilly announced more than $20 billion in U.S. manufacturing investment between 2020 and 2025 to expand tirzepatide capacity. The expansion is partly a response to demand for both Mounjaro and Zepbound, which together exceed Lilly's pre-2024 manufacturing capacity by a wide margin.

Outside the United States, Lilly partners with contract manufacturers and operates additional facilities in Ireland, France, and Italy for global supply.

Zepbound vs Mounjaro: same drug, different brand

This is one of the most common questions about Zepbound. The short answer: Zepbound and Mounjaro are the same active ingredient, tirzepatide, in the same dose strengths, made by the same manufacturer at the same facilities.

The differences are in:

The two products exist as separate brands because the FDA approves drugs by indication, and insurance coverage often depends on the FDA-approved use. A patient with obesity but without type 2 diabetes typically gets Zepbound; a patient with type 2 diabetes typically gets Mounjaro. Both deliver tirzepatide in identical doses.

The active ingredient: tirzepatide

Tirzepatide is a synthetic peptide molecule developed by Lilly. It's a 39-amino-acid peptide modified with a fatty acid chain that allows it to bind to albumin in the blood, extending its half-life to roughly 5 days.

Mechanism of action:

• GLP-1 receptor activation: stimulates insulin release in response to meals, reduces glucagon release, slows gastric emptying, and acts on appetite-regulating regions of the brain to reduce food intake.
• GIP receptor activation: also stimulates insulin release in response to meals; the role in weight loss is less clear but appears to enhance the GLP-1 effect.

The dual mechanism produces larger average weight loss than single-receptor GLP-1 agonists in head-to-head trials. SURMOUNT-1 reported 22.5% mean body weight loss at the 15 mg dose at 72 weeks (Jastreboff et al., NEJM 2022). For comparison, semaglutide (single-receptor GLP-1) reported 14.9% in STEP 1 (Wilding et al., NEJM 2021).

Tirzepatide is not the same molecule as semaglutide, liraglutide, or dulaglutide. It's a separate compound with separate clinical data.

Supply chain and shortage history

Zepbound and Mounjaro had documented shortage status with the FDA from late 2022 through early 2025. The shortage was driven by demand outpacing Lilly's manufacturing capacity, especially after SURMOUNT-1 results made tirzepatide a major obesity treatment.

During the shortage period, the FDA's official drug shortage list included tirzepatide. This shortage status had a specific regulatory consequence: it allowed state-licensed compounding pharmacies to compound tirzepatide for patients with prescriptions, under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act.

In October 2024, the FDA issued a determination that the tirzepatide shortage was resolved, ending the regulatory basis for compounded tirzepatide production. After litigation and a transition period, the FDA finalized the resolution of the shortage in early 2025. Most state-licensed 503A pharmacies stopped compounding tirzepatide by mid-2025.

Compounded tirzepatide is still available through some channels but the regulatory basis is narrower than during the shortage. Compounded products are not FDA-approved and are not interchangeable with Zepbound.

The compounding question

Patients sometimes ask whether compounded tirzepatide is "made by the same company as Zepbound." The answer is no. Compounded tirzepatide is prepared by state-licensed compounding pharmacies, not by Eli Lilly. The pharmacy buys the active ingredient from an FDA-registered API supplier, dilutes it in bacteriostatic water or saline, and dispenses it in vials.

Key differences:

Compounded products are legal when prescribed by a licensed provider and prepared by a licensed pharmacy in compliance with state and federal compounding regulations. Their availability and legal status depend on the FDA shortage list and on state pharmacy law.

FAQ

Who is the manufacturer of Zepbound? Zepbound is manufactured by Eli Lilly and Company, headquartered in Indianapolis, Indiana. Lilly developed the active ingredient (tirzepatide), holds the patent, and produces the finished drug at facilities in Indiana, North Carolina, and Wisconsin.

Is Zepbound made by the same company as Mounjaro? Yes. Both are manufactured by Eli Lilly and Company. Zepbound and Mounjaro contain the same active ingredient (tirzepatide) at the same dose strengths. The brand names differ because Zepbound is approved for weight management while Mounjaro is approved for type 2 diabetes.

When was Zepbound FDA-approved? The FDA approved Zepbound on November 8, 2023, for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition. The indication was expanded in December 2024 to include obstructive sleep apnea in adults with obesity.

Where is Zepbound manufactured? Zepbound is manufactured at Eli Lilly facilities in Indianapolis, Indiana, Concord, North Carolina, and Pleasant Prairie, Wisconsin. Additional capacity at Lebanon, Indiana is scheduled to come online in 2026. All U.S. supply is produced at Lilly facilities.

Is Zepbound made in America? Yes. The U.S. supply of Zepbound is manufactured at Eli Lilly facilities in Indiana, North Carolina, and Wisconsin. Some global supply for international markets is produced at Lilly facilities in Ireland, France, and Italy or at contract manufacturing partners.

Is the active ingredient in Zepbound the same as in Mounjaro? Yes. Both contain tirzepatide as the active ingredient. The molecule, dose strengths (2.5, 5, 7.5, 10, 12.5, 15 mg), and pharmacology are identical. The two brand names exist because of separate FDA approvals for separate indications.

Did Lilly invent tirzepatide? Yes. Lilly research scientists developed tirzepatide internally between 2008 and 2014. Lilly holds the patents on the molecule and on the synthesis methods. The drug is not a generic of any pre-existing GLP-1 medication.

Is Zepbound a generic drug? No. Zepbound is a brand-name drug under patent protection. There is no FDA-approved generic equivalent. Compounded tirzepatide is sometimes mistakenly called a generic; it is not. Generics are FDA-approved equivalents of brand-name drugs after patent expiration. Tirzepatide patents do not expire until at least 2036.

How much does Zepbound cost? Zepbound's list price is approximately $1,060 per month for the auto-injector pen, slightly less for the multi-dose vial format. With insurance coverage, savings cards, or Lilly's direct-to-consumer vial program, out-of-pocket cost varies widely. Discuss with your provider and pharmacy.

Is compounded tirzepatide made by Lilly? No. Compounded tirzepatide is prepared by state-licensed compounding pharmacies, not by Lilly. The compounding pharmacy buys active ingredient from contract API suppliers and prepares it for individual prescriptions. Compounded tirzepatide is not FDA-approved and is not interchangeable with Zepbound.

Why are there shortages of Zepbound? The FDA listed tirzepatide as in shortage from late 2022 through early 2025 because patient demand outpaced Lilly's manufacturing capacity. Lilly invested over $20 billion in expanded U.S. manufacturing capacity, and the FDA declared the shortage resolved in early 2025. Periodic regional supply variation can still occur.

Is Zepbound the same as compounded tirzepatide? No. Zepbound is the FDA-approved brand-name product made by Eli Lilly. Compounded tirzepatide is prepared by state-licensed compounding pharmacies and is not FDA-approved. Quality control, regulatory oversight, and legal status differ. Both contain tirzepatide as the active ingredient but they are not interchangeable.

Related guides

• Who Makes Ozempic and Wegovy: The Single Manufacturer Behind the Global GLP-1 Supply
• Who Makes Ozempic: The Complete Manufacturing and Supply Chain Story Behind the World's Most Prescribed GLP-1
• Who Makes Mounjaro? The Manufacturer, the Molecule, and the Story Behind It
• Who Manufactures Mounjaro? The Single-Source Supply Chain Behind the Tirzepatide Shortage
• Who Manufactures Wegovy: The Complete Story Behind Novo Nordisk's Semaglutide Supply Chain
• Who Manufactures Zepbound? Understanding Eli Lilly's Production, Supply Chain, and What It Means for Compounded Tirzepatide Access

Sources

1. U.S. Food and Drug Administration. FDA Approves New Medication for Chronic Weight Management. Press release, November 8, 2023.
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
3. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515.
4. Eli Lilly and Company. 2024 Annual Report and Form 10-K filings.
5. U.S. Food and Drug Administration. Drug Shortages List. Tirzepatide injection status updates 2022-2025.
6. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
7. Eli Lilly Manufacturing Investments Press Release. May 2024 announcement on Lebanon, Indiana facility.
8. SURMOUNT-OSA trial. Tirzepatide for treatment of obstructive sleep apnea. N Engl J Med. 2024.
9. U.S. Pharmacopeia General Chapter <797> Pharmaceutical Compounding, Sterile Preparations.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Byetta and Trulicity are also trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.